PSY24 COST-EFFECTIVENESS OF HAEMATE P® PROPHYLACTIC TREATMENT FOR BLEEDING EPISODES IN PATIENTS WITH SEVERE VON WILLEBRAND DISEASE  by Gonzalez-Diaz, BE et al.
Abstracts A209
PSY20
COMPARISON OF DOSING PROFILES BETWEEN DULOXETINE AND 
PREGABALIN INITIATORS AMONG ELDERLY PATIENTS WITH 
FIBROMYALGIA
Sun P1, Peng X2, Wu A3, Zhao Y2
1Kailo Research Group, Indianapolis, IN, USA, 2Eli Lilly and Company, Indianapolis, IN, USA, 
3Kailo Research Group, Los Angeles, CA, USA
OBJECTIVES: To assess dosing differences between duloxetine and pregabalin initia-
tors among elderly patients with ﬁbromyalgia. METHODS: Using a large US admin-
istrative claims database, we examined ﬁbromyalgia patients aged 65 and above with 
Medicare supplemental insurance who initiated duloxetine or pregabalin in 2006. 
Initiation was deﬁned as no duloxetine or pregablin pill coverage in the previous 90 
days, with the index date deﬁned as the ﬁrst initiation date. The duloxetine or prega-
balin cohorts were constructed based on the index agent. All individuals selected had 
continuous enrollment in the 12 months pre- and post-index periods and at least 31 
duloxetine or pregabalin supply days in the 12 months post-index period. Duloxetine 
initiators with diabetic peripheral neuropathic pain (DPNP) or depression, and pre-
gabalin initiators with DPNP, post-herpetic neuralgia or epilepsy diagnosis in the 
12-month pre-index period were excluded. Average initial daily dose, annual average 
daily dose, average daily dose of the ﬁrst 12 prescriptions of duloxetine or pregabalin, 
and percent of daily dose change from previous prescription were compared between 
cohorts. RESULTS: Patients in the duloxetine (n = 624) or pregabalin (n = 1,199) 
cohorts had a mean age of 74 years. The average initial daily dose was 51.34 mg for 
duloxetine and 145.71 mg for pregabalin, respectively. Duloxetine patients had an 
annual average daily dose of 50.81 mg, while 162.82 mg for pregabalin patients. The 
average daily dose for the ﬁrst through twelfth duloxetine prescriptions ranged 49.49–
53.96 mg, while the range for pregabalin was between 145.71 mg and 216.96 mg. 
The percentages of changes in daily dose from previous prescriptions were −4.5–2.8% 
for duloxetine and 0.6–12.4% for pregabalin, respectively. CONCLUSIONS: Dulox-
etine and pregabalin had very different dosing proﬁles among elderly patients with 
ﬁbromyalgia. Speciﬁcally, duloxetine initiators had relatively stable average daily dose 
over time, while pregabalin initiators had clear dose escalation over the 12-month 
follow-up period.
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PROJECTING THE ECONOMIC OUTCOMES OF OBESITY USING A 
NATURAL HISTORY MODEL
Wang B1, Garrison L1, Alfonso R1, Flum D2, Arteburn D3, Sullivan S1
1University of Washington, Department of Pharmacy, Seattle, WA, USA, 2University of 
Washington, Department of Surgery, Seattle, WA, USA, 3Group Health Research Institute, 
Seattle, WA, USA
OBJECTIVES: Obesity (deﬁned as body mass index (BMI) > 30) is a major contributor 
to increased morbidity, mortality, and health care expenditures. We used data from 
the Medical Expenditure Panel Survey (MEPS) to construct a lifetime cost and out-
comes model explicitly accounting for morbid obesity. Then, we estimated the poten-
tial economic value of weight reduction in terms of cost savings plus the value of 
improvements in life expectancy and quality of life. METHODS: We constructed a 
Markov model with a lifetime horizon using death and BMI health states: 18.5–24.9, 
25–29.9, 30–34.9, 35–35.9, 40–44.9, 45–49.9, 50 < . MEPS Panels 6–10 (2001–2006) 
provide 91,000 observations to estimate transition probabilities. We estimated dis-
counted (3% per annum) lifetime costs and quality-adjusted life years (QALYs) using 
regressions with gender, age, and BMI as predictors. Utilities were mapped from SF-12 
to EQ-5D. RESULTS: In the base case, for a 45 year-old female with BMI 45–49.9, 
a 10%, 20%, and 30% BMI reduction is associated with discounted lifetime economic 
value gain of $20,000, $35,000, and $51,000, respectively. Transition probability 
estimates show that patients tend to stay in the same BMI category from year to year. 
Average annual cost increases signiﬁcantly (p < 0.01) with BMI (+$362 per 5 BMI 
unit increase), age (+$118 for each year of age) and gender (+$547 for females). For 
utility levels, BMI (−0.0246 per 5 BMI unit increase), age (−0.0036 for each year of 
age), and gender (−0.0355 for females) were all signiﬁcant (p < 0.01). CONCLU-
SIONS: MEPS panels provide repeated measures of BMI allowing a projection of the 
natural history of obesity from a single data source. Obesity is a signiﬁcant driver of 
costs and QALYs: we show that a reduction in BMI of obese patients could be associ-
ated with lower costs and better quality-adjusted life expectancy. MEPS provides only 
self-reported BMI data, and this potential bias deserves further exploration.
PSY22
COST-EFFECTIVENESS OF STRATEGIES FOR DIAGNOSING HEPARIN-
INDUCED THROMBOCYTOPENIA
Patel V, Touchette D, Yang Y, Nutescu E, Kim KS, Vidanovic V, Galanter W
The University of Illinois at Chicago, Chicago, IL, USA
OBJECTIVES: Heparin-induced thrombocytopenia (HIT) is an immune-mediated 
complication of heparin therapy. Accurate diagnosis reduces the need for unnecessary 
treatment, which can result in bleeding complications. The objective of this study was 
to identify the most cost-effective strategy (Enzyme-linked immunosorbent assay 
(ELISA) vs. ELISA/Serotonin Release Assay (SRA)) for diagnosing HIT from the health 
system perspective. METHODS: Multiple decision-analysis models were constructed 
using TreeAge Pro software following the ISPOR task force guidelines for modeling. 
The 2008 American College of Chest Physician’s Guidelines were used to inform HIT 
treatment approaches. A systematic literature search was used to identify all model 
inputs such as the effectiveness of argatroban, heparin, and warfarin; weighted costs 
and disutilities for overall thrombosis and bleeding complications; and costs of acute 
events and long-term complications. Mean age-adjusted quality of life of a healthy 
patient was estimated using life tables. Costs and quality-adjusted life years (QALYs) 
were discounted at 5%. Base-case values were determined using Monte Carlo simula-
tion and sensitivity analyses were conducted. Net beneﬁt of each strategy was analyzed 
at different willingness-to-pay (WTP) thresholds ($0 to $150,000) to determine the 
most cost-effective strategy. RESULTS: In the base-case, ELISA resulted in lifetime 
costs and utilities of $9028 and 10.5413 QALYs compared with $8849 and 10.5428 
QALYs for ELISA/SRA. ELISA was dominated by ELISA/SRA. ELISA/SRA was the 
most cost-effective strategy for WTP thresholds between $25,000 and $150,000; 
ELISA was optimal for WTP thresholds under $25,000. ELISA/SRA remained cost-
effective when thrombosis and bleeding complication costs and probabilities were 
varied. ELISA was the most cost-effective strategy when speciﬁcity was greater than 
92.7%. The results were consistent for both prophylactic and treatment doses of 
unfractionated heparin. CONCLUSIONS: For the base-case scenario, ELISA/SRA is 
the optimal testing strategy. Health care providers need to take into account the 
turnaround time for ELISA and SRA results for generalizing the study ﬁndings.
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A COST-EFFECTIVENESS ANALYSIS OF CONVENTIONAL TREATMENT 
VERSUS BARIATRIC SURGERY FOR OBESE PATIENTS WITH TYPE-2 
DIABETES AND HYPERTENSION AS COMORBIDITIES. PRELIMINARY 
RESULTS UNDER THE BRAZILIAN PRIVATE PAYER PERSPECTIVE
Nasciben V, Saggia MG
Johnson & Johnson, Sao Paulo-SP, Brazil
OBJECTIVES: To assess the cost-effectiveness of the open (OPBARS) and the lapa-
roscopic surgery Roux-en-Y gastric bypass (LAPBARS) versus the conventional non-
surgical treatment (CONVT) for obese patients, in 5 years of follow up, under the 
Brazilian private payer perspective. METHODS: An analytic decision-tree model was 
built to estimate costs and outcomes among OPBARS and LAPBARS versus CONVT, 
measuring weight loss, co morbidities resolution (T-2 diabetes and hypertension; 
Buchwald 2009) and the impact of that on QALYs for obese patients with BMI > 35. 
In order to evaluate the differences of surgery against CONV treatment we assumed 
the same efﬁcacy for OPBARS and LAPBARS. The Brazilian guideline for Health 
Technology Assessment (Vianna, 2007) was the driver for the study development. A 
panel of specialists was conducted to obtain local practice from pre-operatory evalu-
ation to the last medical visit 5 years after the procedure. A micro costing technique 
based on public price lists (SIMPRO 2009, CBHPM 5o Ed) was applied to value the 
resources usage. Only direct medical costs were considered. A discount rate of 5% 
was assumed for costs and outcomes. One-way sensitivity analysis was performed to 
check the robustness of the results. RESULTS: The more sustainable resolution of the 
co morbidities for OPBARS and LAPBARS resulted in an increase of 1.34 QALYs in 
5 years versus CONVT (3.26 QALYs vs. 1.92 QALYs). The total costs for the 5 years 
were R$ 26, 456 for OPBARS, R$ 32,515 for LAPBARS and R$ 19,217 for CONVT. 
So, the incremental cost-effectiveness ratio was R$ 7,449 per QALY for OPBARS 
and R$ 10,395 per QALY for LAPBARS when compared with CONVT. 
CONCLUSIONS: Findings suggest OPBARS and LAPBARS as safer and cost-effective 
choices for obesity treatment and co morbidity resolution, under the Brazilian private 
health care system.
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COST-EFFECTIVENESS OF HAEMATE P® PROPHYLACTIC TREATMENT 
FOR BLEEDING EPISODES IN PATIENTS WITH SEVERE VON 
WILLEBRAND DISEASE
Gonzalez-Diaz BE1, Contreras I2, Martinez-Murillo C1, Alvarez J3, Fuentes-Mendez F3
1Instituto Mexicano del Seguro Social, Mexico, Mexico, 2Instituto Mexicano del Seguro Social, 
Delegación Cuauhtémoc. Distrito Federal, Mexico, 3CSL Behring Biotherapies for life, 
Mexico, Mexico
OBJECTIVES: Patients with sever von Willebrand disease (VWD) are deﬁcient in von 
Willebrand factor (VWF). These deﬁciencies can result in painful and sometimes fatal 
bleeding. The purpose of this study is to develop an economic model for the evaluation 
of cost-effectiveness ratios between Haemate P® and other plasma-derived FVIII/VWF 
concentrates treatment in the control or prophylaxis of urgent bleeding of patients 
with von Willebrand Disease at the Mexican Institute of Social Security (IMSS). 
METHODS: A cost-effectiveness analysis was developed using a Bayesian decision-
tree model. The model simulates costs and effectiveness outcomes in a period of 2O 
days. The comparators were Haemate P® (loading dose 40–60 kg-1 and maintenance 
dose 20–40 U kg-1 every 8–24 h) and plasma-derived FVIII/VWF (dose 20 −50 U 
Kg-1 every 8–24 h). Use of resources and cost data were obtained from expert con-
sensus with hematologist of IMSS. Effectiveness measures were the percentage of 
avoided bleeding. Effectiveness data and transition probabilities were taken from 
international published literature. The model was calibrated according to international 
pharmacoeconomic guidelines. One-way and probabilistic sensitivity analyses were 
performed using second-order Monte Carlo Simulation approach. RESULTS: The 
estimates show that patients who receive Haemate P® prevents might bleeding events 
in 97% while those treated with plasma-derived FVIII/VWF only in the 82%. Mean 
cost per patient treated with Haemate P® (US$4932) was lower than with plasma-
derived FVIII/VWF (US$5,010). Based on ICER’s Haemate P® resulted as the domi-
nant therapy. Acceptability curves showed Haemate P® most cost-effective therapy in 
a range of 80%–90% independently of IMSS willingness to pay. CONCLUSIONS: 
The results show that in México, Haemate P® is the most cost-effective in the pro-
phylaxis of bleeding in patients with VWD at IMSS. These results should be taken 
into account by Mexican decision makers for the management of this disease.
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COST-EFFECTIVENESS OF NONINVASIVE MAGNETIC RESONANCE 
DIRECT THROMBUS IMAGING AND ULTRASONOGRAPHY FOR 
DIAGNOSING DISTAL DEEP VEIN THROMBOSIS
Patel V1, McGhan W2
1The University of Illinois at Chicago, Chicago, IL, USA, 2University of the Sciences in 
Philadelphia, Philadelphia, PA, USA
OBJECTIVES: Proper diagnosis of Deep Vein Thrombosis (DVT) at the earliest time 
is very important so that appropriate therapy can be initiated. Ultrasonography is the 
most widely used diagnostic technique. Noninvasive magnetic resonance direct throm-
bus imaging (MRDTI) is a new diagnostic technique that has higher sensitivity and 
speciﬁcity compared to Ultrasonography for distal deep vein thrombosis (DVT). The 
objective is to identify the most cost-effective strategy for diagnosis of distal deep vein 
thrombosis. METHODS: A decision-analysis model was constructed using TreeAge 
Pro software and analyzed using second-order Monte Carlo simulation technique. 
Diagnostic accuracy was calculated using Bayes’ revision method that utilized sensitiv-
ity and speciﬁcity of the diagnostic tests along with the pretest probability of develop-
ing the disease. Outcomes considered were costs, adverse events and quality of life. 
Quality-adjusted life years were calculated using life expectancy tables. Where appli-
cable, costs in pounds were converted to US dollars and adjusted through use of 
Consumer Price Index data from Bureau of Labor Statistics. Net beneﬁt of each 
strategy was analyzed at different willingness to pay (WTP) thresholds ($0 to 
$150,000) to determine the most cost-effective strategy. RESULTS: Noninvasive MRI 
is the optimal strategy for diagnosis of distal DVT at all WTP thresholds greater than 
$25,000. No diagnosis strategy was the most cost-effective strategy when threshold 
was below $25,000. Sensitivity analysis showed that noninvasive MRI remained cost-
effective even when all costs were varied by 25%. The model results were affected by 
the sensitivity of the diagnostic tests. CONCLUSIONS: For base-case scenario, non-
invasive MRI is the most cost-effective strategy. Considering the cost-effectiveness and 
the fact that ultrasonography has higher mortality compared to noninvasive MRI, 
employing noninvasive MRI appears to the optimal strategy. Health care providers 
should consider patient population distribution among the risk groups deﬁned by 
Wells score for generalizing the study results to their setting.
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COST-EFFECTIVENESS OF SEVELAMER IN THE TREATMENT OF 
HYPERPHOSPHATEMIA ASSOCIATED WITH CHRONIC KIDNEY 
DISEASE IN BRAZIL
Rivas R1, Idrovo J2, Zapata L1
1Guia Mark, Mexico, DF, Mexico, 2National Institute of Public Health, Cuernavaca, Morelos, 
Mexico
OBJECTIVES: The chronic kidney disease (CKD) is associated with an abnormally 
elevated level of phosphate in the blood, which contributes to the presence of vascular 
calciﬁcations, thus increasing the probability of the occurrence of cardiovascular 
events and death in these patients. The objective of this analysis was to evaluate the 
incremental cost-effectiveness of the use of sevelamer to manage hyperphosphatemia 
in Brazil METHODS: A Markov model was created to estimate the monthly costs 
and beneﬁts of the treatment with sevelamer or calcium tablets in patients with renal 
failure considering a temporary horizon of 60 months. The transition probabilities 
were taken from clinical trials identiﬁed through a systematic review of literature. The 
effectiveness measure considered was an increase in patient survival (months). Only 
direct costs were considered . Costs were calculated using 2009 prices and are 
expressed in US dollars. In addition, univariate sensitivity analysis and scenario 
changes were performed. The discount rate was 5%. RESULTS: The expected cost 
was US$37,477 for calcium and US$58,397 for sevelamer. Patients in calcium group 
would survive 51 months, compared to the sevelamer group (54 months). The Cost-
Effectiveness Ratio with calcium was $734 and with sevelamer was $1073 respec-
tively, and the incremental Cost-Effectiveness Ratio for the implementation of 
sevelamer vs. calcium was $6135 .(1 USD = 1.8 BRL$) CONCLUSIONS: Sevelamer 
is a cost-effective drug for the treatment of hyperphosphatemia in patients with CKD 
in the brazilian context.
PSY27
COST-EFFECTIVENESS OF SEVELAMER IN THE TREATMENT OF 
HYPERPHOSPHATEMIA ASSOCIATED WITH CHRONIC KIDNEY 
DISEASE IN ARGENTINA
Rivas R1, Idrovo J2, Zapata L1
1Guia Mark, Mexico, DF, Mexico, 2National Institute of Public Health, Cuernavaca, Morelos, 
Mexico
OBJECTIVES: The chronic kidney disease (CKD) is associated with an abnormally 
elevated level of phosphate in the blood, which contributes to the presence of vascular 
calciﬁcations, thus increasing the probability of the occurrence of cardiovascular 
events and death in these patients. The objective of this analysis was to evaluate the 
incremental cost-effectiveness of the use of sevelamer to manage hyperphosphatemia 
in Argentina METHODS: A Markov model was created to estimate the monthly costs 
and beneﬁts of the treatment with sevelamer or calcium tablets in patients with renal 
failure considering a temporal horizon of 60 months. The transition probabilities were 
taken from clinical trials identiﬁed through a systematic review of literature. The 
effectiveness measure considered was an increase in patient survival (months). Only 
direct costs were considered . Costs were calculated using 2009 prices and are 
expressed in US dollars. In addition, univariate sensitivity analysis and scenario 
changes were performed. The discount rate was 5%. Exchange rate was 3.6 Argentine 
pesos (ARS) per 1 US dollar. RESULTS: The expected cost was US$52,558 for calcium 
and US$69,678 for sevelamer. Patients in calcium group would survive 51 months, 
compared to the sevelamer group (54 months). The Cost-Effectiveness Ratio with 
calcium was US$1030 and with sevelamer was US$1280 respectively, and the incre-
mental Cost-Effectiveness Ratio for the implementation of sevelamer vs. calcium was 
US$5021. ICER of sensitivity analysis doesn’t change more than 10% of original 
scenario. CONCLUSIONS: Sevelamer is a cost-effective drug for the treatment of 
hyperphosphatemia in patients with CKD in the Argentinian context.
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COST-EFFECTIVENESS ANALYSIS OF CELECOXIB FOR THE 
MANAGEMENT OF LOW BACK PAIN AT THE SOCIAL SECURITY 
MEXICAN INSTITUTE
Arreola-Ornelas H1, Rosado-Buzzo A1, García-Mollinedo L1, Dorantes-Aguilar L2, 
Muciño-Ortega E3, Mould-Quevedo JF3
1Links & Links, Mexico City, Mexico, 2Links & Links, Mexico City, Mexico, Mexico, 3Pﬁzer 
S.A. de C.V., México City, Mexico
OBJECTIVES: The aim of this research was to estimate from an institutional perspec-
tive the cost-effectiveness of celecoxib against other usual analgesics for the treatment 
of adult patients with low-back pain. METHODS: A complete economic evaluation 
was conducted using a Markov model. Four health-states were used by the Markov 
model to assess the disease history within a 12-month time horizon. Treatments used 
in the evaluation were: Celecoxib 200 mg/day, naproxen 1 gr/day (oral) for 14 days; 
diclofenac 150 mg/day (intramuscular) for two days followed by diclofenac 200 mg/
day (oral) for 12 days; tramadol/acetaminophen 75 mg/day (oral) for 14 days and 
acetaminophen 1500 mg/day (oral) for 14 days. Effectiveness measures were: mean 
reduction of pain >50% vs. baseline (through visual analog scale questionnaire) and 
mean reduction in days of hospitalization. Hospital records were collected in several 
institutional Mexico City hospitals (n = 15,723). Unit costs were obtained from clinical 
records and ofﬁcial databases from patients seen in the Social Security Mexican 
Institute. Probabilistic sensitivity analyses were performed employing bootstrapping 
techniques and acceptability curves were constructed. RESULTS: Celecoxib treatment 
showed the highest mean pain reduction with 57% [CI95% 55–58%] followed by 
tramadol/acetaminophen with 46% [45–48%] and acetaminophen with 42% [40–
43%]. The celecoxib-treated group also showed the lowest rate of hospitalization 0.17 
[0.16–0.18] followed by tramadol/acetaminophen with 0.19 [0.19–0.20] and naproxen 
with 0.23 [0.23–0.24]. Celecoxib showed an ICER of US$471.71 for the mean pain 
reduction and US$1,088.48 for the mean reduction of hospitalized days measurement 
against diclofenac (case base). The latter was conﬁrmed by Monte Carlo ﬁrst-order 
simulations and acceptability curves. CONCLUSIONS: Celecoxib was more cost-
effective as a treatment for adult patients with low back-pain (higher effectiveness 
with low annual costs) than other usual analgesics.
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MODELING THE COST-EFFECTIVENESS OF BORTEZOMIB FOR THE 
INITIAL TREATMENT OF MULTIPLE MYELOMA IN THE UNITED STATES
Wang ST1, Huang H2, Shi H2, Duh MS1, Chen K1, Chang E1, Korves C1, Dhawan R3, 
Cakana A4, van de Velde H5, Esseltine DL2, Garrison L6
1Analysis Group, Inc., Boston, MA, USA, 2Millennium: The Takeda Oncology Company, 
Cambridge, MA, USA, 3Johnson & Johnson Pharmaceutical Services L.L.C, Raritan, NJ, USA, 
4Janssen-Cilag Ltd, Saunderton, High Wycombe, UK, 5Johnson & Johnson ORD, Beerse, 
Belgium, 6University of Washington, Department of Pharmacy, Seattle, WA, USA
OBJECTIVES: The current study aimed to compare the lifetime health outcomes and 
cost-effectiveness of bortezomib plus melphalan and prednisone (VMP) relative to 
melphalan and predisone alone (MP), and indirectly to thalidomide plus MP (MPT), 
for the initial treatment of multiple myeloma (MM) in the non-transplant setting. 
METHODS: A Markov model from a US payer’s perspective was developed. Simula-
tions were performed on hypothetical cohorts of newly diagnosed MM patients ineli-
gible for transplant. The model included seven health states representing periods of 
treatment response, treatment-free interval, progressive disease, second-line treatment, 
and death. Monthly transition probabilities were estimated from patient-level phase 
III VISTA trial data for VMP and MP (June 15, 2007 data cut-off) and from the 
published phase III IFM 99–06 trial for MPT (Facon et al, Lancet 2007). Costs 
included per-protocol drug and medical costs, treatment-related adverse events, sec-
ond-line treatment, and resource utilization during treatment-free interval and pro-
gressive disease. All costs were adjusted to 2009 US dollars. State-speciﬁc utility 
estimates were derived from patient-level EQ-5D data from VISTA using US-speciﬁc 
weights. Health outcomes were expressed in life-years (LYs) and quality-adjusted 
life-years (QALYs). Both cost and health outcomes were discounted at 3%. RESULTS: 
The model estimated 4.187 LYs (2.994 QALYs) with VMP versus 2.864 LYs (2.049 
QALYs) with MP and 4.140 LYs (2.951 QALYs) with MPT. Lifetime direct medical 
costs are $110,870 for VMP versus $57,864 for MP and $129,902 for MPT. Cost 
per LY and QALY gained with VMP versus MP is $40,051 and $56,109, respectively. 
VMP is dominant versus MPT, costing 17.7% less and providing slightly more 
QALYs. CONCLUSIONS: The incremental cost-effectiveness of VMP versus MP is 
within the generally accepted range of $50,000 to $100,000 per QALY, suggesting 
that VMP is cost-effective versus MP in the US. VMP is dominant versus MPT, yielding 
lower costs and better health outcomes.
